BlackRock
ABUS icon

BlackRock’s Arbutus Biopharma ABUS Stock Holding History

BlackRock’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.4M Sell
12,966,946
-85,915
-0.7% -$376K ﹤0.01% 2413
2025
Q4 		$62.8M Buy
13,052,861
+375,365
+3% +$1.69M ﹤0.01% 2375
2025
Q3 		$57.6M Sell
12,677,496
-191,790
-1% -$704K ﹤0.01% 2416
2025
Q2 		$39.8M Buy
12,869,286
+102,664
+0.8% +$341K ﹤0.01% 2592
2025
Q1 		$44.6M Sell
12,766,622
-170,832
-1% -$570K ﹤0.01% 2431
2024
Q4 		$42.3M Buy
12,937,454
+718,695
+6% +$2.64M ﹤0.01% 2559
2024
Q3 		$47M Buy
12,218,759
+666,693
+6% +$2.56M ﹤0.01% 2503
2024
Q2 		$35.7M Buy
11,552,066
+1,147,447
+11% +$3.44M ﹤0.01% 2614
2024
Q1 		$26.8M Buy
10,404,619
+14,319
+0.1% +$37.1K ﹤0.01% 2820
2023
Q4 		$26M Buy
10,390,300
+116,159
+1% +$227K ﹤0.01% 2858
2023
Q3 		$20.9M Buy
10,274,141
+304,614
+3% +$639K ﹤0.01% 2922
2023
Q2 		$22.9M Buy
9,969,527
+1,505,441
+18% +$3.92M ﹤0.01% 2947
2023
Q1 		$25.6M Sell
8,464,086
-236,306
-3% -$667K ﹤0.01% 2842
2022
Q4 		$20.3M Buy
8,700,392
+1,232,574
+17% +$2.95M ﹤0.01% 3036
2022
Q3 		$14.3M Sell
7,467,818
-72,564
-1% -$171K ﹤0.01% 3226
2022
Q2 		$20.4M Buy
7,540,382
+715,553
+10% +$1.83M ﹤0.01% 3077
2022
Q1 		$20.3M Buy
6,824,829
+658,480
+11% +$2.02M ﹤0.01% 3164
2021
Q4 		$24M Buy
6,166,349
+231,146
+4% +$898K ﹤0.01% 3171
2021
Q3 		$25.5M Buy
5,935,203
+99,630
+2% +$332K ﹤0.01% 3125
2021
Q2 		$17.7M Buy
5,835,573
+3,737,863
+178% +$11.6M ﹤0.01% 3379
2021
Q1 		$6.99M Buy
2,097,710
+276,603
+15% +$1.07M ﹤0.01% 3781
2020
Q4 		$6.46M Buy
1,821,107
+775,713
+74% +$2.72M ﹤0.01% 3585
2020
Q3 		$3.27M Buy
1,045,394
+831,118
+388% +$2.53M ﹤0.01% 3748
2020
Q2 		$390K Buy
214,276
+110,605
+107% +$181K ﹤0.01% 4258
2020
Q1 		$105K Buy
103,671
+5,134
+5% +$13.9K ﹤0.01% 4342
2019
Q4 		$274K Sell
98,537
-570,019
-85% -$922K ﹤0.01% 4277
2019
Q3 		$1.02M Buy
668,556
+10,267
+2% +$17.7K ﹤0.01% 3974
2019
Q2 		$1.37M Sell
658,289
-1,653,843
-72% -$4.23M ﹤0.01% 3910
2019
Q1 		$8.28M Sell
2,312,132
-112,550
-5% -$432K ﹤0.01% 3203
2018
Q4 		$9.29M Buy
2,424,682
+2,461
+0.1% +$12.1K ﹤0.01% 3129
2018
Q3 		$22.9M Buy
2,422,221
+31,078
+1% +$309K ﹤0.01% 2796
2018
Q2 		$17.5M Buy
2,391,143
+1,701,237
+247% +$10.1M ﹤0.01% 2943
2018
Q1 		$3.45M Sell
689,906
-61,408
-8% -$325K ﹤0.01% 3534
2017
Q4 		$3.79M Buy
751,314
+741,576
+7,615% +$4.35M ﹤0.01% 3525
2017
Q3 		$60K Buy
+9,738
New +$41.7K ﹤0.01% 4448
2014
Q4 		– Sell
-53,800
Closed -$1.14M – 3150
2014
Q3 		$1.14M Sell
53,800
-4,400
-8% -$71.8K ﹤0.01% 1186
2014
Q2 		$760K Hold
58,200
– – ﹤0.01% 1259
2014
Q1 		$1.25M Buy
+58,200
New +$1.05M ﹤0.01% 1160

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock's ABUS Position: Q1 2026 in Review

BlackRock reduced its Arbutus Biopharma (ABUS) stake by 0.66% in Q1 2026, selling an estimated $376K and leaving 12,966,946 shares worth $58.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2413.

BlackRock first reported a position in ABUS in Q1 2014 and has held it in 38 quarters since. The position peaked at $62.8M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • BlackRock held 12,966,946 shares of Arbutus Biopharma worth $58.4M as of Q1 2026.
  • BlackRock sold 85,915 Arbutus Biopharma shares in Q1 2026, an estimated $376K.
  • Arbutus Biopharma made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2413 holding.
  • BlackRock first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 38 quarters since.
  • BlackRock's Arbutus Biopharma position peaked at $62.8M in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.